X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GSK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GSK PHARMA PANACEA BIOTECH/
GSK PHARMA
 
P/E (TTM) x -21.9 67.5 - View Chart
P/BV x 2.6 13.6 19.1% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 PANACEA BIOTECH   GSK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GSK PHARMA
Mar-18
PANACEA BIOTECH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1492,760 5.4%   
Low Rs822,040 4.0%   
Sales per share (Unadj.) Rs84.1339.0 24.8%  
Earnings per share (Unadj.) Rs-18.341.4 -44.2%  
Cash flow per share (Unadj.) Rs-6.745.9 -14.6%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs83.7242.9 34.5%  
Shares outstanding (eoy) m61.2584.70 72.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.47.1 19.4%   
Avg P/E ratio x-6.357.9 -10.9%  
P/CF ratio (eoy) x-17.252.3 -33.0%  
Price / Book Value ratio x1.49.9 14.0%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m7,074203,280 3.5%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,4495,234 27.7%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,15428,715 17.9%  
Other income Rs m100545 18.3%   
Total revenues Rs m5,25429,260 18.0%   
Gross profit Rs m-7665,059 -15.1%  
Depreciation Rs m711380 187.1%   
Interest Rs m1,5032 75,150.0%   
Profit before tax Rs m-2,8815,222 -55.2%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771178 994.9%   
Tax Rs m171,892 0.9%   
Profit after tax Rs m-1,1213,508 -32.0%  
Gross profit margin %-14.917.6 -84.4%  
Effective tax rate %-0.636.2 -1.6%   
Net profit margin %-21.812.2 -178.1%  
BALANCE SHEET DATA
Current assets Rs m3,81021,815 17.5%   
Current liabilities Rs m8,36515,999 52.3%   
Net working cap to sales %-88.420.3 -436.4%  
Current ratio x0.51.4 33.4%  
Inventory Days Days15664 244.8%  
Debtors Days Days6719 359.8%  
Net fixed assets Rs m14,48012,475 116.1%   
Share capital Rs m61847 7.2%   
"Free" reserves Rs m90319,726 4.6%   
Net worth Rs m5,12720,573 24.9%   
Long term debt Rs m5,8326 97,195.0%   
Total assets Rs m19,43339,475 49.2%  
Interest coverage x-0.92,612.0 -0.0%   
Debt to equity ratio x1.10 390,002.5%  
Sales to assets ratio x0.30.7 36.5%   
Return on assets %2.08.9 22.1%  
Return on equity %-21.917.1 -128.3%  
Return on capital %3.626.2 13.9%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,539564 272.9%   
Fx outflow Rs m9427,429 12.7%   
Net fx Rs m597-6,865 -8.7%   
CASH FLOW
From Operations Rs m5994,728 12.7%  
From Investments Rs m-438-1,042 42.0%  
From Financial Activity Rs m-303-3,066 9.9%  
Net Cashflow Rs m-141620 -22.8%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.6 10.2 5.9%  
FIIs % 1.3 23.8 5.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 15.4 153.2%  
Shareholders   10,259 102,036 10.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  ALEMBIC LTD  MERCK LTD  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 19, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS